PRECISION BIOSCIENCES INC — Director's Dealing 2019

Mar 29, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27

Reporting Person: Schinazi Raymond F (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-27	Stock Option (Right to Buy)	$16.00	A	34544	Acquired	2029-03-26	Common Stock (34544)	Direct
2019-03-27	Convertible Promissory Note	$13.60	J		Acquired		Common Stock (36946)	Indirect

Footnotes

F1: The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months.

F2: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F3: The 2019 Note is held of record by RFS. RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.